Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1

Robert A Hauser¹, Ruosha Li², Adriana Pérez², Xuehan Ren², Dan Weintraub³, Jordan Elm⁴, John L Goudreau⁵, John C Morgan⁶, John Y Fang⁷, Michael J Aminoff⁸, Chadwick W Christine⁸, Rohit Dhall⁹, Chizoba C Umeh¹⁰, James T Boyd¹¹, Natividad Stover¹², Maureen Leehey¹³, Richard M Zweig¹⁴, Anthony P Nicholas¹⁵, Ivan Bodis-Wollner¹⁶, Allison Willis¹⁷, Karl Kieburtz¹⁸, Barbara C Tilley²; NINDS NET-PD Investigators

Affiliations

¹ Departments of Neurology, Molecular Pharmacology and Physiology, University of South Florida, Parkinson's Disease and Movement Disorders Center, National Parkinson Foundation Center of Excellence, Tampa FL, USA.
² Department of Biostatistics, The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, Houston, TX, USA.
³ Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
⁴ Medical University of South Carolina, Department of Public Health Sciences, Charleston, SC, USA.
⁵ Department of Neurology, Michigan State University, East Lansing, MI, USA.
⁶ National Parkinson Foundation Center of Excellence, Movement Disorders Program, Department of Neurology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
⁷ Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
⁸ University of California, San Francisco, Department of Neurology, University of California, San Francisco, CA, USA.
⁹ The Parkinson's Institute and Clinical Center, Sunnyvale, CA, USA.
¹⁰ Division of Movement Disorders, Brigham and Women's Hospital, Boston, MA, USA.
¹¹ Department of Neurological Sciences, University of Vermont, College of Medicine, Burlington, VT, USA.
¹² Department of Neurology, The University of Alabama at Birmingham, Birmingham, AL, USA.
¹³ Department of Neurology, University of Colorado, School of Medicine, Aurora, CO, USA.
¹⁴ Department of Neurology, Louisiana State University Health Sciences Center in Shreveport, Shreveport, LA, USA.
¹⁵ Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
¹⁶ Departments of Neurology and Ophthalmology, Parkinson's Disease and Related Disorders Clinic, Center of Excellence, State University of New York, Downstate Medical Center, Brooklyn, NY, USA.
¹⁷ Department of Neurology, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
¹⁸ University of Rochester, Center for Human Experimental Therapeutics, Rochester, NY, USA.

PMID: 27911341
DOI: 10.3233/JPD-160965

Free article

Randomized Controlled Trial

Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1

Robert A Hauser et al. J Parkinsons Dis. 2017.

Free article

. 2017;7(1):117-127.

doi: 10.3233/JPD-160965.

Authors

Affiliations

¹ Departments of Neurology, Molecular Pharmacology and Physiology, University of South Florida, Parkinson's Disease and Movement Disorders Center, National Parkinson Foundation Center of Excellence, Tampa FL, USA.
² Department of Biostatistics, The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, Houston, TX, USA.
³ Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
⁴ Medical University of South Carolina, Department of Public Health Sciences, Charleston, SC, USA.
⁵ Department of Neurology, Michigan State University, East Lansing, MI, USA.
⁶ National Parkinson Foundation Center of Excellence, Movement Disorders Program, Department of Neurology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
⁷ Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
⁸ University of California, San Francisco, Department of Neurology, University of California, San Francisco, CA, USA.
⁹ The Parkinson's Institute and Clinical Center, Sunnyvale, CA, USA.
¹⁰ Division of Movement Disorders, Brigham and Women's Hospital, Boston, MA, USA.
¹¹ Department of Neurological Sciences, University of Vermont, College of Medicine, Burlington, VT, USA.
¹² Department of Neurology, The University of Alabama at Birmingham, Birmingham, AL, USA.
¹³ Department of Neurology, University of Colorado, School of Medicine, Aurora, CO, USA.
¹⁴ Department of Neurology, Louisiana State University Health Sciences Center in Shreveport, Shreveport, LA, USA.
¹⁵ Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
¹⁶ Departments of Neurology and Ophthalmology, Parkinson's Disease and Related Disorders Clinic, Center of Excellence, State University of New York, Downstate Medical Center, Brooklyn, NY, USA.
¹⁷ Department of Neurology, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
¹⁸ University of Rochester, Center for Human Experimental Therapeutics, Rochester, NY, USA.

PMID: 27911341
DOI: 10.3233/JPD-160965

Abstract

Background: Monoamine oxidase type B (MAO-B) inhibitors exhibit neuroprotective effects in preclinical models of PD but clinical trials have failed to convincingly demonstrate disease modifying benefits in PD patients.

Objective: To perform a secondary analysis of NET-PD LS1 to determine if longer duration of MAO-B inhibitor exposure was associated with less clinical decline.

Methods: The primary outcome measure was the Global Outcome (GO), comprised of 5 measures: change from baseline in the Schwab and England (ADL) scale, the 39-item Parkinson's Disease Questionnaire (PDQ-39), the UPDRS Ambulatory Capacity Scale, the Symbol Digit Modalities Test, and the most recent Modified Rankin Scale. A linear mixed model was used to explore the association between the cumulative duration of MAO-B inhibitor exposure and the GO, adjusting for necessary factors and confounders. Associations between MAO-B inhibitor exposure and each of the five GO components were then studied individually.

Results: 1616 participants comprised the analytic sample. Mean observation was 4.1 (SD = 1.4) years, and 784 (48.5%) participants received an MAO-B inhibitor. The regression coefficient of cumulative duration of MAO-B inhibitor exposure (in years) on the GO was - 0.0064 (SE = 0.002, p = 0.001). Significant associations between duration of MAO-B inhibitor exposure and less progression were observed for ADL (p < 0.001), Ambulatory Capacity (p < 0.001), and the Rankin (p = 0.002).

Conclusions: Our analysis identified a significant association between longer duration of MAO-B inhibitor exposure and less clinical decline. These findings support the possibility that MAO-B inhibitors slow clinical disease progression and suggest that a definitive prospective trial should be considered.

Keywords: MAO-B inhibitor; Parkinson’s disease; disease modification; rasagiline; selegiline; treatment.

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1

Affiliations

Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical